Abstract:Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (NELM) is thought to afford the best long-term outcomes when feasible. Initial preoperative workup should include surveillance for carcinoid syndrome, screening for evidence of liver insufficiency, and performance of imaging specific to neuroendocrine tumors such as a somatostatin receptor positron emission tomography scan. Standard surgical principles apply to hepatic surgery for NELM, namely prioritizing low central venous pressure anesthesia, minimizing blood loss, knowledge of liver anatomy, generous use of intraoperative ultrasound, as well as safe parenchymal transection techniques and practices to avoid bile leakage. Knowledge of established prognostic factors may assist with patient selection, which is important for optimizing short- and long-term outcomes of hepatic resection. Adjunct therapies such as concomitant liver ablation are used frequently and are generally safe when used appropriately. For patients with synchronous resectable NELM, resection of the primary either in a staged or combined fashion is recommended. Primary tumor resection in the setting of unresectable metastatic disease is more controversial, however generally recommended if morbidity is acceptable. For patients who are not surgical candidates, due to either patient performance status or burden of liver disease, several liver-directed therapies such as transarterial embolization, chemoembolization, and radioembolization are available to assist with locoregional control, extend progression-free survival (PFS), and improve symptoms of carcinoid syndrome. Multiple systemic therapy options exist for patients with metastatic PNET which are often prioritized for those patients with advanced or progressive disease. A systematic approach in a multi-disciplinary setting is likely to result in the best long-term outcomes for patients with pancreatic NELM. Ongoing research is needed to determine the optimal patient selection for hepatic surgery as well as the ideal treatment sequencing for those patients with NELM.

Comprehensive treatment for advanced pancreatic neuroendocrine neoplasm

Role of Surgical Treatments in High-Grade or Advanced Gastroenteropancreatic Neuroendocrine Neoplasms.

Treatment of Primary Hepatic Neuroendocrine Tumors

Initial Treatment Strategy of Pancreatic Neuroendocrine Neoplasms

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

[Surgical Treatment for Pancreatic Neuroendocrine Neoplasmas].

The comprehensive treatment of metastatic pancreatic neuroendocrine tumors

Diagnosis and Surgical Treatment of Pancreatic Neuroendocrine Neoplasms

The Advance in Research into Immunotherapy for Neuroendocrine Carcinoma of Digestive System

Long‐term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report

Surgical management of pancreatic neuroendocrine liver metastases

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

[Treatment Strategies of Pancreatic Neuroendocrine Neoplasms with Liver Metastases].

Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis

[The Treatment Options of Pancreatic Neuroendocrine Neoplasm with Liver Metastasis].

Reflections on hot issues of pancreatic neuroendocrine neoplasms

Systemic Therapy for Pancreatic Neuroendocrine Tumors

Clinical Efficacy of the Laparoscopic Resection for Pancreatic Neuroendocrine Neoplasms

[Controversies and Prospects for Surgical Treatment of Pancreatic Neuroendocrine Neoplasms with Liver Metastases].

Multidisciplinary Approach for the Management of Metastatic Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas

[Advances in Immunotherapy for Neuroendocrine Neoplasms].